Celyad Oncology S.A.
CYADNASDAQHealthcare
$0.47
$-0.07(-12.96%)
Market Cap$14238462
P/E Ratio—
52W High$3.07
52W Low$0.15
Celyad Oncology S.A. (CYAD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CYAD · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2024Report Date: Jun 30, 2024EPS Actual
-$0.13
Revenue
$0.00B
Fiscal Period
Q2 FY2024
FY ends December
Report Date
Jun 30, 2024
After Market Close
✓ 1-Quarter EPS Beat Streak
CYAD reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q2 FY2024 | Jun 30, 2024 | — | -$0.13 | — | $0.00B | — | — |
| — Q4 FY2023 | Dec 30, 2023 | — | -$0.18 | — | $0.00B | — | — |
| — Q2 FY2023 | Jun 30, 2023 | — | -$0.18 | — | $0.00B | — | — |
| ◌ Q1 FY2023 | Mar 23, 2023 | — | — | — | — | — | — |
| — Q4 FY2022 | Dec 31, 2022 | — | -$1.28 | — | — | — | — |
| — Q3 FY2022 | Aug 5, 2022 | — | -$0.30 | — | — | — | — |
| — Q1 FY2022 | Mar 24, 2022 | — | -$0.37 | — | — | — | — |
| — Q4 FY2021 | Dec 31, 2021 | — | -$0.15 | — | — | — | — |
Q2 FY2024
Jun 30, 2024
EPS Actual
-$0.13
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2023
Dec 30, 2023
EPS Actual
-$0.18
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2023
Jun 30, 2023
EPS Actual
-$0.18
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2023
Mar 23, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2022
Dec 31, 2022
EPS Actual
-$1.28
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2022
Aug 5, 2022
EPS Actual
-$0.30
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2022
Mar 24, 2022
EPS Actual
-$0.37
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2021
Dec 31, 2021
EPS Actual
-$0.15
EPS Est.
—
EPS Surpr.
—
Revenue
—
No analyst estimates available for CYAD.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2024 | Jun 30, 2024 | — | $0.47 | — | — |
| — Q4 FY2023 | Dec 30, 2023 | — | $0.47 | — | — |
| — Q2 FY2023 | Jun 30, 2023 | — | $0.47 | — | — |
| — Q4 FY2022 | Dec 31, 2022 | — | $0.49 | $0.50 | +1.44% |
| — Q3 FY2022 | Aug 5, 2022 | — | $2.03 | $2.44 | +20.20% |
| — Q1 FY2022 | Mar 24, 2022 | — | $2.39 | $2.35 | -1.67% |
| — Q4 FY2021 | Dec 31, 2021 | — | $3.74 | $3.66 | -2.14% |
| — Q3 FY2021 | Sep 30, 2021 | — | $4.11 | $4.10 | -0.24% |
Q2 FY2024—
Report Date
Jun 30, 2024
EPS Beat/Miss
—
Price Before
$0.47
Price After
—
Q4 FY2023—
Report Date
Dec 30, 2023
EPS Beat/Miss
—
Price Before
$0.47
Price After
—
Q2 FY2023—
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$0.47
Price After
—
Q4 FY2022+1.44%
Report Date
Dec 31, 2022
EPS Beat/Miss
—
Price Before
$0.49
Price After
$0.50
Q3 FY2022+20.20%
Report Date
Aug 5, 2022
EPS Beat/Miss
—
Price Before
$2.03
Price After
$2.44
Q1 FY2022-1.67%
Report Date
Mar 24, 2022
EPS Beat/Miss
—
Price Before
$2.39
Price After
$2.35
Q4 FY2021-2.14%
Report Date
Dec 31, 2021
EPS Beat/Miss
—
Price Before
$3.74
Price After
$3.66
Q3 FY2021-0.24%
Report Date
Sep 30, 2021
EPS Beat/Miss
—
Price Before
$4.11
Price After
$4.10
Beat Rate0 / 8 quarters
Largest Move+20.20% (Q3 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CYAD ends December
Celyad Oncology S.A. (CYAD) most recently reported earnings on June 30, 2024 for Q2 FY2024, posting EPS of $-0.13 (in line with the analyst consensus of —). The next CYAD earnings date is expected around September 1, 2026.
Each quarter, investors track CYAD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CYAD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CYAD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CYAD earnings · 4 questionsCelyad Oncology S.A.'s next earnings report is expected around September 1, 2026. CYAD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CYAD historically reports after market close (AMC).
CYAD earnings datewhen is CYAD earningsCYAD next earnings datewhen does CYAD report earningsCYAD earnings calendar
▸ Source: FMP · Celyad Oncology S.A. SEC filings · US GAAP · Celyad Oncology S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026